Patents by Inventor Brian D. Lawrence
Brian D. Lawrence has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11890328Abstract: A protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: GrantFiled: June 28, 2021Date of Patent: February 6, 2024Assignee: Silk Technologies, Ltd.Inventors: Brian D. Lawrence, David W. Infanger
-
Publication number: 20220411482Abstract: A biotherapeutic ophthalmic solution that may include a silk-derived protein as an active ingredient. Ophthalmic formulations are critical to the delivery of dosage forms, user requirements, and maintaining product stability. The formulations described herein are ophthalmic solutions that are comfortable to the user while product stability is maintained, even after long-term storage. Numerous excipients, manufacturing processes, and container closures were evaluated for their ability to stabilize silk-derived protein under ambient and accelerated conditions. Analyses showed that a small sub-set of protein-containing formulations meet the high physiochemical property standards required for therapeutic ophthalmic solutions.Type: ApplicationFiled: November 16, 2020Publication date: December 29, 2022Applicant: SILK TECHNOLOGIES, LTD.Inventors: Brian D. Lawrence, David W. Infanger, Yue Bai, Nicholas Paulson
-
Publication number: 20220332773Abstract: Described herein are methods for reducing inflammation by administration of an effective amount of silk-derived proteins (SDP) or a fraction thereof to a subject having an inflammatory condition. The methods include the treatment of inflammatory conditions and wounds, including corneal wounds, comprising the topical administration of an effective amount of SDP material as described herein.Type: ApplicationFiled: February 7, 2022Publication date: October 20, 2022Applicant: Silk Technologies, Ltd.Inventors: Brian D. LAWRENCE, David W. INFANGER
-
Publication number: 20220054596Abstract: A protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: ApplicationFiled: June 28, 2021Publication date: February 24, 2022Applicant: Silk Technologies, Ltd.Inventors: Brian D. LAWRENCE, David W. INFANGER
-
Patent number: 11242367Abstract: Described herein are methods for reducing inflammation by administration of an effective amount of silk-derived proteins (SDP) or a fraction thereof to a subject having an inflammatory condition. The methods include the treatment of inflammatory conditions and wounds, including corneal wounds, comprising the topical administration of an effective amount of SDP material as described herein.Type: GrantFiled: August 12, 2017Date of Patent: February 8, 2022Assignee: Silk Technologies, Ltd.Inventors: Brian D. Lawrence, David W. Infanger
-
Publication number: 20220017602Abstract: A biotherapeutic ophthalmic solution that may include a silk-derived protein as an active ingredient. The specific formulation of an ophthalmic composition is critical to meeting user requirements, to the delivery of dosage forms, and to maintaining product stability. The formulations described herein are ophthalmic solutions that are comfortable to the user while product stability is maintained, even after long-term storage. Numerous excipients, manufacturing processes, and container closures were evaluated for their ability to stabilize silk-derived protein under ambient and accelerated conditions. Analyses showed that only a very small subset of vehicle formulations were able to meet the high physiochemical property standards required for stabilizing protein-containing therapeutic ophthalmic solution formulations.Type: ApplicationFiled: July 15, 2021Publication date: January 20, 2022Applicant: Silk Technologies, Ltd.Inventors: Brian D. LAWRENCE, David W. INFANGER, Yue BAI, Nicholas PAULSON
-
Patent number: 11045524Abstract: A protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: GrantFiled: November 11, 2019Date of Patent: June 29, 2021Assignee: Silk Technologies, Ltd.Inventors: Brian D. Lawrence, David W. Infanger
-
Patent number: 10953132Abstract: Described herein are methods of enhancing wound healing using silk-derived proteins (SDP), including low molecular weight SDP fragments. Also described are compositions for the treatment of wounds, including corneal wounds, skin wounds, surgical incisions, burns, and skin ulcers, comprising SDP fragments, including low molecular weight SDP fragments.Type: GrantFiled: April 7, 2017Date of Patent: March 23, 2021Assignees: Cornell University, Silk Technologies, Ltd.Inventors: Waleed Abdel-Naby, Mark Rosenblatt, Brian D. Lawrence, David W. Infanger
-
Publication number: 20200171131Abstract: A protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: ApplicationFiled: November 11, 2019Publication date: June 4, 2020Applicant: Silk Technologies, Ltd.Inventors: Brian D. LAWRENCE, David W. INFANGER
-
Patent number: 10471128Abstract: The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: GrantFiled: March 5, 2018Date of Patent: November 12, 2019Assignee: Silk Technologies, Ltd.Inventors: Brian D. Lawrence, David W. Infanger
-
Publication number: 20190169243Abstract: Described herein are methods for reducing inflammation by administration of an effective amount of silk-derived proteins (SDP) or a fraction thereof to a subject having an inflammatory condition. The methods include the treatment of inflammatory conditions and wounds, including corneal wounds, comprising the topical administration of an effective amount of SDP material as described herein.Type: ApplicationFiled: August 12, 2017Publication date: June 6, 2019Applicant: Silk Technologies, Ltd.Inventors: Brian D. LAWRENCE, David W. INFANGER
-
Publication number: 20190117834Abstract: Described herein are methods of enhancing wound healing using silk-derived proteins (SDP), including low molecular weight SDP fragments. Also described are compositions for the treatment of wounds, including corneal wounds, skin wounds, surgical incisions, burns, and skin ulcers, comprising SDP fragments, including low molecular weight SDP fragments.Type: ApplicationFiled: April 7, 2017Publication date: April 25, 2019Applicants: Cornell University, Silk Technologies, Ltd.Inventors: Waleed ABDEL-NABY, Mark ROSENBLATT, Brian D. LAWRENCE, David W. INFANGER
-
Patent number: 10064817Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: GrantFiled: October 28, 2011Date of Patent: September 4, 2018Assignee: Meda Pharmaceuticals Inc.Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
-
Publication number: 20180193429Abstract: The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: ApplicationFiled: March 5, 2018Publication date: July 12, 2018Applicant: Silk Technologies, Ltd.Inventors: Brian D. LAWRENCE, David W. INFANGER
-
Patent number: 9919050Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions, into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: GrantFiled: August 23, 2013Date of Patent: March 20, 2018Assignee: Meda Pharmaceuticals Inc.Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
-
Patent number: 9907836Abstract: The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: GrantFiled: July 15, 2016Date of Patent: March 6, 2018Assignee: Silk Technologies, Ltd.Inventors: Brian D. Lawrence, David W. Infanger
-
Publication number: 20160331815Abstract: The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: ApplicationFiled: July 15, 2016Publication date: November 17, 2016Applicant: Silk Technologies, Ltd.Inventors: Brian D. Lawrence, David W. Infanger
-
Patent number: 9394355Abstract: The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: GrantFiled: August 20, 2015Date of Patent: July 19, 2016Assignee: Silk Technologies, Ltd.Inventors: Brian D. Lawrence, David W. Infanger
-
Publication number: 20160096878Abstract: The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.Type: ApplicationFiled: August 20, 2015Publication date: April 7, 2016Applicant: SILK TECHNOLOGIES, LTD.Inventors: Brian D. Lawrence, David W. Infanger
-
Publication number: 20140193466Abstract: The present invention provides for silk-derived compositions for treating a wide variety of ocular conditions. The composition is produced by processing the silk cocoon into a water-based solution (i.e., a dissolved silk), which is then cast into a film. The film may be transparent to visible light, and curved in shape for easy application to the ocular surface. The silk film may either self-adhere or be sutured to cover the wound. The degradation time of the film may range from 1 minute to 24 hours, or from 2 hours to 20 hours. The present compositions can help regenerate damaged corneal tissue, thus promoting healing.Type: ApplicationFiled: June 7, 2012Publication date: July 10, 2014Applicant: CORNELL UNIVERSITYInventors: Brian D Lawrence, Alejandro Navas, Mark I. Rosenblatt